Has sold a drug candidate to a major pharmaceutical company for DKK 623 million.
Action Pharma has developed a drug to prevent acute kidney failure in cardiac surgery.
The company originated from research at Aarhus University led by professor of biomedicine Søren Nielsen and professor of clinical physiology and nuclear medicine Jørgen Frøkiær.
Action Pharma was founded in 2002 and CAPNOVA entered the same year with venture capital as the first investor.
In 2012, Action Pharma’s primary drug candidate AP214 was sold to US pharmaceutical giant Abbott for DKK 623 million. The company was then closed down and CAPNOVA and the other investors, including the Danish venture company Sunstone ended up with a nice profit.
The deal between Action Pharma and Abbott is one of the largest single-drug deals on a global scale.
Have a look at some of our other companies
Read more about some of our other companies that are on their way to the top and others that have already made it.
Our current companies
Explore our entire portfolio
Companies that went all the way